Eli Lilly (LLY) Total Current Liabilities (2009 - 2026)

Eli Lilly has reported Total Current Liabilities for 18 years, with the latest figure at $36.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 21.84% year-over-year to $36.6 billion; the trailing twelve-month figure through Mar 2026 stood at $36.6 billion (up 21.84% YoY), and the FY2025 full-year result was $35.2 billion, up 24.15% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $36.6 billion, up from $35.2 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $40.1 billion in Q3 2025, with the low at $13.4 billion in Q1 2022.
• Historically, Total Current Liabilities has averaged $25.1 billion across 5 years, with a median of $24.7 billion in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities grew 3.49% — and 2025, when it jumped 62.68%.
• Eli Lilly's Total Current Liabilities stood at $17.1 billion in 2022, then jumped by 59.25% to $27.3 billion in 2023, then climbed by 3.97% to $28.4 billion in 2024, then climbed by 24.15% to $35.2 billion in 2025, then rose by 3.99% to $36.6 billion in 2026.
• The last three Total Current Liabilities figures came in at $36.6 billion (Q1 2026), $35.2 billion (Q4 2025), and $40.1 billion (Q3 2025), per Business Quant data.